FAQ · GLP-1 · Editorial commentary

What does the Mounjaro Patient Information Leaflet say about missed doses?

Editorial commentary on the published Patient Information Leaflet. The MHRA-approved PIL for Mounjaro (tirzepatide) contains a missed-dose section describing what the manufacturer recommends if a weekly dose is missed, including a time window after which the missed dose should be skipped. PeptideClear does not reproduce the specific instructions because the authoritative source is the PIL in the medication box and on emc.medicines.org.uk, and because your prescriber's individual instructions take precedence over any third-party summary. If you have missed a dose, the right step is to read the PIL supplied with your medication and contact your prescriber, your pharmacist, or NHS 111 if you are unsure.

If you have missed a dose right now, read the Patient Information Leaflet supplied with your medication and contact your prescriber. If you cannot reach your prescriber and are unsure what to do, call NHS 111. Your prescriber\'s instructions for your individual case take precedence over any general written summary.

Why we do not reproduce the missed-dose instruction here

Mounjaro is a UK prescription-only medicine. The instruction for what to do if a dose is missed is set out in the MHRA-approved Patient Information Leaflet supplied in the medication box and published on emc.medicines.org.uk. That document is the authoritative source. A general consumer website is not the right place to reproduce a specific clinical instruction, because the right action also depends on factors a third-party website cannot know: which dose you are on, where you are in titration, how long ago your last dose was, and what your prescriber has told you to do.

What the published pharmacology describes

Editorial commentary only. Published pharmacology for tirzepatide describes a half-life of approximately five days, which is why the medication is given as a weekly injection. The shape of the missed-dose recommendation in the PIL follows from that half-life, but the precise time window referenced, and the actions inside and outside that window, are set out in the PIL itself.

If you have missed several consecutive weeks

This is a scenario the PIL does not cover in detail and where prescriber input is particularly important. UK prescribers commonly review titration history before recommending how to restart, because restarting at a previous maintenance dose after a prolonged gap can be poorly tolerated. The right contact in this case is your prescriber, not a general website.

Travel and storage

The PIL covers storage conditions, including how long the pen can be kept outside the fridge and the maximum room temperature. These details are set out in the storage section of the PIL and on the pen carton. For travel scenarios that change your usual injection day, the PIL\'s storage and timing guidance, plus a quick check with your prescriber or pharmacist, is the appropriate route.

Where to ask

· The PIL supplied with your medication, or the version published on emc.medicines.org.uk.
· Your prescriber: NHS GP, private clinic prescriber, or pharmacist prescriber.
· Your dispensing pharmacist.
· NHS 111 if you cannot reach your prescriber and are unsure what to do.
· Adverse effects can be reported via MHRA Yellow Card.

Decision routing: missed-dose action is a clinical decision. The PIL is the published instruction, your prescriber\'s individual guidance takes precedence, and NHS 111 is the safety net. This page is editorial commentary, not clinical advice.